Melbourne, Australia – May 29, 2026 – Kalohexis, a pioneering biopharmaceutical company dedicated to revolutionizing metabolic disease treatment, has announced a significant milestone: the successful dosing of the first patients in its Phase I first-in-human clinical trial of 710GO. This groundbreaking oral medication is designed to target the melanocortin system, a crucial regulator of appetite and metabolism, offering a potential paradigm shift in the management of general obesity.
The meticulously designed trial, conducted in Australia, is poised to enroll approximately 100 healthy volunteers who are either overweight or obese. This initial human study will rigorously assess the pharmacodynamics, pharmacokinetics, preliminary efficacy, safety, and tolerability of 710GO, a dual melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R) agonist. The initiation of this trial marks a critical step forward in the development of a potentially more sustainable and less burdensome approach to weight loss, addressing the limitations of current therapeutic options.
The Promise of 710GO: A New Approach to Weight Regulation
Obesity is a complex, chronic disease affecting billions worldwide, carrying significant risks for numerous co-morbidities including cardiovascular disease, type 2 diabetes, certain cancers, and osteoarthritis. While recent advancements in anti-obesity medications, particularly GLP-1 receptor agonists, have demonstrated remarkable efficacy in promoting weight loss, they are not without their challenges. These include potential side effects such as gastrointestinal distress, the risk of losing lean body mass, and the often-observed phenomenon of weight regain upon cessation of treatment.
710GO distinguishes itself through its innovative mechanism of action. By targeting both MC3R and MC4R, it aims to reset the body’s natural metabolic set point. The melanocortin system plays a pivotal role in regulating energy balance, and activating these specific receptors is believed to promote more sustained weight management by influencing satiety, energy expenditure, and fat metabolism. This dual-receptor activation is theorized to foster a more durable metabolic state, potentially mitigating the issues of rapid weight regain and lean mass loss associated with other therapies.
Trial Design and Objectives: A Comprehensive Evaluation
The Phase I clinical trial for 710GO is a robust, randomized, double-blind, placebo-controlled study. This rigorous design ensures that the data collected is unbiased and reliable. The trial incorporates several key components to comprehensively evaluate the drug:
- Single-Ascending Dose (SAD) Component: This part of the study will administer a single dose of 710GO to different groups of participants, gradually increasing the dose to assess initial safety and tolerability.
- 28-Day Multiple-Ascending Dose (MAD) Component: Following the SAD phase, participants will receive multiple doses of 710GO over a 28-day period. This will provide crucial information on how the drug is absorbed, distributed, metabolized, and excreted (pharmacokinetics) and its ongoing effects on the body (pharmacodynamics) with repeated administration.
- Food Effect Component: This aspect of the trial will investigate how the presence or absence of food affects the absorption and overall profile of 710GO, informing optimal dosing strategies.
The primary objectives of this Phase I trial are to:
- Assess Safety and Tolerability: Determine the safety profile of 710GO across a range of doses and identify any potential adverse events.
- Characterize Pharmacokinetics (PK): Understand how the body handles 710GO, including its absorption, peak concentration, distribution, metabolism, and elimination.
- Evaluate Pharmacodynamics (PD): Measure the drug’s effects on biological markers related to appetite, metabolism, and energy balance.
- Gather Preliminary Efficacy Data: Obtain initial insights into the drug’s ability to induce weight loss and improve metabolic parameters.
The recruitment of approximately 100 healthy overweight or obese volunteers is crucial for establishing a baseline understanding of 710GO’s effects in a relevant population. The trial’s location in Australia offers a favorable regulatory environment and access to experienced clinical research sites.
Preclinical Evidence: A Strong Foundation for Human Studies
The transition of 710GO into human trials is underpinned by compelling preclinical data, particularly from studies conducted in non-human primates. These studies provided significant evidence for the drug’s unique mechanism and its potential to overcome the limitations of existing treatments.
In diet-induced obesity models in non-human primates, daily oral administration of 710GO demonstrated consistent and significant weight loss. Over a 13-week treatment period, these primates experienced an average body weight reduction of 11.7%. Critically, this weight loss was primarily driven by a decrease in fat mass, a highly desirable outcome in obesity management, as opposed to a significant loss of metabolically active lean body mass.
Furthermore, the preclinical assessments highlighted a favorable safety and tolerability profile for 710GO. No significant gastrointestinal or cardiovascular adverse events were reported in these animal studies, suggesting a potentially cleaner side-effect profile compared to some current anti-obesity medications.
Perhaps one of the most promising findings from the preclinical research was 710GO’s potential for sustained weight management. In studies where 710GO was used in combination with semaglutide (a widely used GLP-1 receptor agonist), synergistic effects were observed, leading to even greater weight reductions than with monotherapy. Crucially, the data also suggested less rapid weight regain after treatment cessation, hinting at a more durable effect on the body’s metabolic regulation. This suggests that 710GO could serve as a standalone therapy or be effectively integrated into combination treatment regimens for a more comprehensive and lasting impact on weight management.
Expert Perspectives: A Vision for the Future of Obesity Treatment
The initiation of this Phase I trial represents a significant moment for Kalohexis and the broader field of obesity research. Russell Potterfield, CEO of Kalohexis, expressed his enthusiasm and the strategic importance of this development:
“Dosing the first cohort of patients marks a major milestone for Kalohexis and the development of 710GO, our lead obesity asset with the potential to overcome the limitations of current standard of care treatment for general obesity,” stated Potterfield. “The melanocortin system is the body’s natural regulator of metabolic homeostasis, and 710GO is a novel peptide that activates both MC3R/MC4R to establish a new metabolic set point for the body to actively maintain. 710GO is a convenient oral therapy and represents a differentiated treatment option for general obesity with the potential to enable healthier, more durable weight loss.”
Potterfield’s remarks underscore the scientific rationale behind 710GO. By leveraging the body’s innate regulatory systems, the drug aims to achieve weight loss that is not merely a temporary outcome but a sustained shift in metabolic function. The convenience of an oral formulation further enhances its appeal, offering a less invasive and potentially more accessible treatment option for individuals struggling with obesity.
Implications and the Road Ahead
The successful completion of this Phase I trial will pave the way for subsequent clinical development. If 710GO demonstrates a favorable safety profile and promising efficacy signals, it will advance to Phase II studies, which will involve larger patient populations and further explore optimal dosing and therapeutic potential.
The implications of a successful 710GO therapy are far-reaching:
- Improved Patient Outcomes: A drug that promotes sustainable weight loss with fewer side effects could significantly improve the quality of life for millions of individuals with obesity, reducing their risk of associated health complications.
- Enhanced Treatment Options: 710GO’s potential as a standalone therapy or in combination with existing treatments offers clinicians and patients a broader and more personalized toolkit for managing obesity.
- Reduced Healthcare Burden: By effectively managing obesity and its co-morbidities, new therapies like 710GO could contribute to a reduction in the significant economic burden that obesity places on healthcare systems globally.
- Innovation in Metabolic Disease: The development of 710GO highlights the ongoing innovation in understanding and targeting complex metabolic pathways, fostering further research and development in this critical area of medicine.
The journey from preclinical promise to approved therapy is long and complex, but the initiation of this Phase I trial for 710GO represents a significant stride forward. Kalohexis’s commitment to unlocking the potential of the melanocortin system offers a beacon of hope for a future where obesity can be managed more effectively, sustainably, and with greater patient well-being at its core. The scientific community and patients alike will be keenly observing the progress of this innovative oral therapy as it embarks on its critical first steps in human clinical trials.
About the Author
